"A 24-MONTH, PHASE IIIB, RANDOMIZED, DOUBLE-MASKED, MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF TWO TREATMENT REGIMENS OF 0.5MG RANIBIZUMAB INTRAVITREAL INJECTIONS GUIDED BY FUNCTIONAL AND/OR ANATOMICAL CRITERIA, IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (OCTAVE)."
- Registry ID
- CRFB002A2405
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2011-12-08
- Last update
- 2013-04-03
Conditions
- NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Related clinical trials
- A RANDOMIZED, CONTROLLED, PARTIALLY MASKED, PHASE 3B STUDY TO ASSESS THE INJECTION BURDEN, EFFICACY, SAFETY, AND LONG-TERM PRESERVATION OF VISUAL ACUITY OF SURABGENE LOMPARVOVEC (ABBV-RGX-314) IN A REAL-WORLD CONTEXT IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- HIGH DOSE (HD) AFLIBERCEPT SWITCH IN NAMD:
TO LOAD OR MAINTAIN? (HEIRLOOM)
- A PHASE IIIB/IV, MULTICENTER, RANDOMIZED, OPEN-LABEL, TWO ARM STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND
DURABILITY OF FARICIMAB ADMINISTERED UP TO EVERY 24 WEEKS
IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR
DEGENERATION (CONSTANCE)
- HOME OCT-GUIDED TREATMENT VERSUS TREAT AND EXTEND FOR THE MANAGEMENT OF NEOVASCULAR AMD
- A RANDOMIZED, PARTIALLY MASKED, CONTROLLED, PHASE 3 CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RGX-314 GENE THERAPY IN PARTICIPANTS WITH NAMD
- A PHASE 3, MULTICENTRE, DOUBLE-MASKED, RANDOMISED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL OPT-302 IN COMBINATION WITH RANIBIZUMAB, COMPARED WITH RANIBIZUMAB ALONE, IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
View on source registry